Arecor Therapeutics PLC (AIM:AREC) CEO Sarah Howell talked with Proactive’s Stephen Gunnion about the company’s progress in developing next-generation treatments for diabetes and other cardio metabolic diseases, with a particular focus on its lead insulin candidate AT278 and its oral peptide delivery platform.
Howell explained that Arecor is advancing AT278, an ultra-concentrated, ultra-rapid-acting insulin designed for use in automated insulin delivery (AID) systems. The company is targeting a significant unmet need among patients requiring intensive insulin therapy, particularly those who struggle with current pump limitations. She noted: “AT278 is the only insulin that meets this profile… and of course, we’ve shown superiority against those best-in-class insulins.”
The company has made strong progress over the past year, including a co-development partnership with Sequel Med Tech to support a planned Phase 2 clinical trial in the US. Arecor also reported a positive FDA Type C meeting, giving confidence in the study design and regulatory pathway. The Phase 2 trial is expected to begin in the second half of 2026.
Beyond insulin, Arecor is developing an oral peptide delivery platform, initially focused on GLP-1 therapies. Howell highlighted that the company has successfully stabilised the peptide and is now working to improve bioavailability, a key challenge in oral delivery.
With a strengthened balance sheet and multiple upcoming milestones, Arecor is positioning itself to advance both its clinical and platform programmes in large, high-value markets.
For more videos like this, visit Proactive’s YouTube channel, like this video, subscribe, and enable notifications so you never miss an update.
#Arecor #AT278 #DiabetesTreatment #InsulinTherapy #Biotech #GLP1 #HealthcareInnovation #MedTech #ClinicalTrials #PharmaNews #DrugDevelopment #Investing #Biotechnology #AIDSystems #ObesityTreatment
